Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Consultation

Evolucumab draft recommendations

The National Institute for Health and Care Excellence (NICE) has issued draft guidance not recommending evolocumab (Repatha, Amgen) as an option for people with high cholesterol (primary hypercholesterolaemia — heterozygous-familial and non-familial) and mixed dyslipidaemia. The draft guidance can be accessed via the NICE website and comments submitted until 8 December 2015.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200138

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.